Neuropeptide Y: An Anti-Aging Player?

Trends in Neurosciences

Volumn 38, Issue 11, 2015, Pages 701-711

  Botelho, Mariana ^a,b   Cavadas, Cláudia ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Autophagy; Caloric restriction; Hallmarks of aging; Inflammation; Neuropeptide Y; Senescence; Stem cells

Indexed keywords

ADIPONECTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GONADORELIN; GROWTH HORMONE; HEAT SHOCK PROTEIN 72; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROLINE; SIGNAL PEPTIDE; SIRTUIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

AGING; ARCUATE NUCLEUS; BRAIN LEVEL; CALORIC RESTRICTION; CELL COMMUNICATION; CELL INTERACTION; CELL PROLIFERATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; LATERAL HYPOTHALAMUS; METABOLIC REGULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN QUALITY; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; BRAIN; CELL AGING; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

AGING; ANIMALS; BRAIN; CALORIC RESTRICTION; CELL AGING; HUMANS; MITOCHONDRIA; NEUROPEPTIDE Y;

EID: 84947762860     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.08.012     Document Type: Review

References (126)

1. Tatemoto K., et al. Neuropeptide Y: a novel brain peptide whit structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
2. Michel M.C., et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50:143-150.
3. Silva A.P., et al. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:331-347.
4. Michalkiewicz M., et al. Hypotension and reduced catecholamines in neuropeptide Y transgenic rats. Hypertension 2003, 41:1056-1062.
5. Redrobe J.P., et al. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J. Mol. Neurosci. 2004, 22:159-166.
6. Hedden T., Gabrieli J.D.E. Insights into the ageing mind: a view from cognitive neuroscience. Nat. Rev. Neurosci. 2004, 5:87-96.
7. López-Otín C., et al. The hallmarks of aging. Cell 2013, 153:1194-1217.
8. Gehrig S.M., et al. Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 2012, 484:394-398.
9. Panossian A., et al. Adaptogens stimulate neuropeptidey and Hsp72 expression and release in neuroglia cells. Front. Neurosci. 2012, 6:1-12.
10. Levine B., Klionsky D.J. Development by self-digestionmolecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6:463-477.
11. Rubinsztein D.C., et al. Autophagy and aging. Cell 2011, 146:682-695.
12. Komatsu M., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
13. Blagosklonny M.V. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell Death Dis. 2010, 1:e12.
14. Hansen M., et al. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet. 2008, 4:e24.
15. Minor R.K., et al. Hungry for life: how the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction. Mol. Cell 2009, 299:79-88.
16. Aveleira C.A., et al. Neuropeptide Y stimulates autophagy in hypothalamic neurons. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:1642-1651.
17. Barzilai N., et al. The critical role of metabolic pathways in aging. Diabetes 2012, 61:1315-1322.
18. Kenyon C.J. The genetics of ageing. Nature 2010, 464:504-512.
19. Berdichevsky A., et al. C. elegans SIR-2.1 Interacts with 14-3-3 proteins to activate DAF-16 and extend life span. Cell 2006, 125:1165-1177.
20. Hong S.H., et al. Minibrain/Dyrk1a regulates food intake through the Sir2-FOXO-sNPF/NPY pathway in Drosophila and mammals. PLoS Genet. 2012, 8:1-15.
21. Härfstrand A., et al. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regul. Pept. 1987, 17:167-179.
22. Suzuki N., et al. Inhibitory effect of neuropeptide Y on growth hormone secretion in rats is mediated by both Y1- and Y2-receptor subtypes and abolished after anterolateral deafferentation of the medial basal hypothalamus. Regul. Pept. 1996, 65:145-151.
23. Barb C.R., Barrett J.B. Neuropeptide Y modulates growth hormone but not luteinizing hormone secretion from prepuberal gilt anterior pituitary cells in culture. Domest. Anim. Endocrinol. 2005, 29:548-555.
24. Peng C., et al. Neuropeptide-Y stimulates growth hormone and gonadotropin-ii secretion in the goldfish pituitary: involvement of both presynaptic and pituitary cell actions. Endocrinology 1993, 132:1820-1829.
25. Cho S.J., et al. Intracerebroventricular and intravenous administration of growth hormone secretagogue L-692,585, somatostatin, neuropeptide Y and galanin in pig: dose-dependent effects on growth hormone secretion. Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 2010, 151:412-419.
26. Marston O.J., et al. Neuropeptide Y cells represent a distinct glucose-sensing population in the lateral hypothalamus. Endocrinology 2011, 152:4046-4052.
27. Maejima Y., et al. Insulin suppresses ghrelin-induced calcium signaling in neuropeptide Y neurons of the hypothalamic arcuate nucleus. Aging 2011, 3:1092-1097.
28. Fioramonti X., et al. Characterization of glucosensing neuron subpopulations in the arcuate nucleus. Diabetes 2007, 56:1219-1227.
29. Van den Top M., et al. Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus. Nat. Neurosci. 2004, 7:493-494.
30. Morley J.E. Anorexia, sarcopenia, and aging. Nutrition 2001, 9007:660-663.
31. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2006, 361:1159-1185.
32. Mckibbin P.E., et al. Altered neuropeptide Y concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Diabetes 1991, 40:1423-1429.
33. Goldstone A.P., et al. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J. Clin. Endocrinol. Metab. 2002, 87:927-937.
34. Zahorska-Markiewicz B., et al. Neuropeptide Y in obese women during treatment with adrenergic modulation drugs. Med. Sci. Monit. 2001, 7:403-408.
35. Hansen M.J., et al. Adaptive responses in hypothalamic neuropeptide Y in the face of prolonged high-fat feeding in the rat. J. Neurochem. 2004, 88:909-916.
36. Minor R.K., et al. The arcuate nucleus and NPY contribute to the antitumorigenic effect of calorie restriction. Aging Cell 2011, 10:483-492.
37. Kallio J., et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 2001, 15:1242-1244.
38. Kaipio K., Pesonen U. The intracellular mobility of NPY and a putative mitochondrial form of NPY in neuronal cells. Neurosci. Lett. 2009, 450:181-185.
39. Kir H.M., et al. Effects of single-dose neuropeptide Y on levels of hippocampal BDNF, MDA, GSH, and NO in a rat model of pentylenetetrazole-induced epileptic seizure. Bosn. J. Basic Med. Sci. 2013, 13:242-247.
40. Zhang L., et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int. J. Obes. 2010, 34:357-373.
41. Campisi J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2013, 75:685-705.
42. Zukowska-Grojec Z., et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 1998, 83:187-195.
43. Kitlinska J., et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 2005, 65:1719-1728.
44. Lu C., et al. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 2010, 29:5630-5642.
45. Sheriff S., et al. Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Mol. Cancer Res. 2010, 8:604-614.
46. Li J., et al. Neuropeptide Y Y1 receptors meditate targeted delivery of anticancer drug encapsulating nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy. ACS Appl. Mater. Interfaces 2015, 7:5574-5582.
47. Burton D.G., Krizhanovsky V. Physiological and pathological consequences of cellular senescence. Cell. Mol. Life Sci. 2014, 71:4373-4386.
48. Medina S., et al. Age-related changes in the modulatory action of gastrin-releasing peptide, neuropeptide Y and sulfated cholecystokinin octapeptide in the proliferation of murine lymphocytes. Neuropeptides 1999, 33:173-179.
49. Medina S., et al. The NPY effects on murine leukocyte adherence and chemotaxis change with age: adherent cell implication. Regul. Pept. 2000, 95:35-45.
50. Puerto M., et al. Modulation of neuropeptide Y and norepinephrine on several leucocyte functions in adult, old and very old mice. J. Neuroimmunol. 2005, 165:33-40.
51. De la Fuente M., et al. Neuropeptide Y effects on murine natural killer activity: changes with ageing and cAMP involvement. Regul. Pept. 2001, 101:73-79.
52. De la Fuente M., et al. Effect of aging on the modulation of macrophage functions by neuropeptides. Life Sci. 2000, 67:2125-2135.
53. De la Fuente M., et al. Changes with aging in the modulation by neuropeptide Y of murine peritoneal macrophage functions. J. Neuroimmunol. 2001, 116:156-167.
54. Bedoui S., et al. Neuropeptide Y receptor-specifically modulates human neutrophil function. J. Neuroimmunol. 2008, 195:88-95.
55. Son M.Y., et al. Involvement of neuropeptide Y and its Y1 and Y5 receptors in maintaining self-renewal and proliferation of human embryonic stem cells. J. Cell. Mol. Med. 2011, 15:152-165.
56. Igura K., et al. Neuropeptide y and neuropeptide y y5 receptor interaction restores impaired growth potential of aging bone marrow stromal cells. Rejuvenation Res. 2011, 14:393-403.
57. Lee N.J., et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J. Bone Miner. Res. 2010, 25:1736-1747.
58. Park M.H., et al. Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow. EMBO J. 2015, 34:1648-1660.
59. Doyle K.L., et al. Y1 receptors are critical for the proliferation of adult mouse precursor cells in the olfactory neuroepithelium. J. Neurochem. 2008, 105:641-652.
60. Alvaro A.R., et al. Neuropeptide Y stimulates retinal neural cell proliferation: involvement of nitric oxide. J. Neurochem. 2008, 105:2501-2510.
61. Thiriet N., et al. NPY promotes chemokinesis and neurogenesis in the rat subventricular zone. J. Neurochem. 2011, 116:1018-1027.
62. Agasse F., et al. Neuropeptide Y promotes neurogenesis in murine subventricular zone. Stem Cells 2008, 26:1636-1645.
63. Stanic D., et al. Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3610-3615.
64. Howell O.W., et al. Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol. Dis. 2007, 26:174-188.
65. Howell O.W., et al. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J. Neurochem. 2005, 93:560-570.
66. Decressac M., et al. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol. Dis. 2009, 34:441-449.
67. Decressac M., et al. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus 2011, 21:233-238.
68. Kokoeva M.V., et al. Evidence for constitutive neural cell proliferation in the adult murine hypothalamus. J. Comp. Neurol. 2007, 505:209-220.
69. Higuchi H., et al. Age-related bidirectional changes in neuropeptide Y peptides in rat adrenal glands, brain, and blood. J. Neurochem. 1988, 50:1879-1886.
70. Gruenewald D.A., et al. Age-related decrease in neuropeptide-Y gene expression in the arcuate nucleus of the male rat brain is independent of testicular feedback. Endocrinology 1994, 134:2383-2389.
71. Zhang G., et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature 2013, 497:211-216.
72. Ma W., et al. Neuropeptides stimulate human osteoblast activity and promote gap junctional intercellular communication. Neuropeptides 2013, 47:179-186.
73. Roa J., Herbison A.E. Direct regulation of GnRH neuron excitability by arcuate nucleus POMC and NPY neuron neuropeptides in female mice. Endocrinology 2012, 153:5587-5599.
74. Ferreira R., et al. Neuropeptide y modulation of interleukin-1β (IL-1β)-induced nitric oxide production in microglia. J. Biol. Chem. 2010, 285:41921-41934.
75. Li Q., et al. Neuropeptide Y protects cerebral cortical neurons by regulating microglial immune function. Neural Regen. Res. 2014, 9:959.
76. Ferreira R., et al. Neuropeptide y inhibits interleukin-1 beta-induced microglia motility. J. Neurochem. 2012, 120:93-105.
77. Ferreira R., et al. Neuropeptide Y inhibits interleukin-1β-induced phagocytosis by microglial cells. J. Neuroinflammation 2011, 8:169.
78. Zhou J.R., et al. Neuropeptide Y promotes TGF-β1 production in RAW264.7 cells by activating PI3K pathway via Y1 receptor. Neurosci. Bull. 2008, 24:155-159.
79. Buttari B., et al. Neuropeptide y induces potent migration of human immature dendritic cells and promotes a Th2 polarization. FASEB J. 2014, 28:3038-3049.
80. Jääskeläinen A.E., et al. Systemic treatment with neuropeptide Y receptor Y1-antagonist enhances atherosclerosis and stimulates IL-12 expression in ApoE deficient mice. Neuropeptides 2013, 47:67-73.
81. Karvonen M.K., et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001, 159:145-151.
82. Lagraauw H.M., et al. Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. Atherosclerosis 2014, 235:196-203.
83. Madeo F., et al. Caloric restriction mimetics: towards a molecular definition. Nat. Rev. Drug Discov. 2014, 13:727-740.
84. Sajdyk T.J., et al. Amygdalar neuropeptide Y Y 1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol. 1999, 368:143-147.
85. Redrobe J.P., et al. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY- induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
86. Corp E.S., et al. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides 2001, 22:493-499.
87. Thiele T.E., et al. Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J. Neurosci. 2002, 22:RC208.
88. Silva A.P., et al. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 2003, 17:1118-1120.
89. Sainsbury A., et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8938-8943.
90. El Bahh B., et al. Blockade of neuropeptide Y(2) receptors and suppression of NPY's anti-epileptic actions in the rat hippocampal slice by BIIE0246. Br. J. Pharmacol. 2002, 136:502-509.
91. Santos-Carvalho A., et al. Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis. 2013, 4:e636.
92. Soscia S.J., Harrington M.E. Neuropeptide Y does not reset the circadian clock in NPY Y2-/- mice. Neurosci. Lett. 2005, 373:175-178.
93. Redrobe J.P., et al. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav. Brain Res. 2003, 141:251-255.
94. Horvath T.L., et al. A GABA-neuropeptide Y (NPY) interplay in LH release. Peptides 2001, 22:473-481.
95. Campbell R.E., et al. Orexin neurons express a functional pancreatic polypeptide Y4 receptor. J. Neurosci. 2003, 23:1487-1497.
96. Mashiko S., et al. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp34NPY. Endocrinology 2003, 144:1793-1801.
97. Benmaamar R., et al. Neuropeptide Y Y 5 receptors inhibit kindling acquisition in rats. Regul. Pept. 2005, 125:79-83.
98. Morales-Medina J.C., et al. The selective neuropeptide Y Y5 agonist [cPP1-7,NPY19-23,Ala31,Aib32, Gln34]hPP differently modulates emotional processes and body weight in the rat. Behav. Brain Res. 2012, 233:298-304.
99. Cha C.I., et al. Age-related changes of VIP, NPY and somatostatin-immunoreactive neurons in the cerebral cortex of aged rats. Brain Res. 1997, 753:235-244.
100. Kowalski C., et al. Age-related changes in cortico-releasing factor, somatostatin, neuropeptide Y, methionine enkephalin and beta-endorphin in specific rat brain areas. Brain Res. 1992, 582:38-46.
101. Huh Y., et al. Age-related change in the neuropeptide Y and NADPH-diaphorase-positive neurons in the cerebral cortex and striatum of aged rats. Neurosci. Lett. 1997, 223:157-160.
102. Allen J.M., et al. Dissociation of neuropeptide Y and somatostatin in Parkinson's disease. Brain Res. 1985, 337:197-200.
103. Dawbarn D., et al. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 1985, 340:251-260.
104. Mazurek M.F., et al. Cortical peptide changes in Huntington's Disease may be independent of striatal degeneration. Ann. Neurol. 1997, 41:540-547.
105. Davies C.A., et al. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J. Neurol. Sci. 1990, 96:59-73.
106. Beal M.F., et al. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann. Neurol. 1988, 23:562-569.
107. Veyrat-Durebex C., et al. Aging and long-term caloric restriction regulate neuropeptide Y receptor subtype densities in the rat brain. Neuropeptides 2013, 47:163-169.
108. Hwang I.K., et al. Age-related change of neuropeptide Y-immunoreactive neurons in the rat anterior olfactory nucleus. J. Neurocytol. 2001, 30:967-972.
109. Masoro E.J. Dietary restriction-induced life extension: a broadly based biological phenomenon. Biogerontology 2006, 7:153-155.
110. Mattison J.A., et al. Impact of caloric restriction on health and survival in rhesus monkeys: the NIA study. Nature 2012, 489:318-321.
111. Colman R.J., et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
112. Bi S. Role of dorsomedial hypothalamic neuropeptide Y in energy homeostasis. Peptides 2007, 28:352-356.
113. Chiba T., et al. A key role for neuropeptide Y in lifespan extension and cancer suppression via dietary restriction. Sci. Rep. 2014, 4:4517.
114. Radler M.E., et al. Calorie restriction increases lipopolysaccharide-induced neuropeptide Y immunolabeling and reduces microglial cell area in the arcuate hypothalamic nucleus. Neuroscience 2015, 285:236-247.
115. Ruscica M., et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 2006, 147:1466-1473.
116. Yang K., et al. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J. 2008, 22:2452-2464.
117. Ekstrand A.J., et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6033-6038.
118. Medeiros P.J., et al. Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. Int. J. Cancer 2012, 131:276-286.
119. Kuo L.E., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 2007, 13:803-811.
120. Rosmaninho-Salgado J., et al. Intracellular mechanisms coupled to NPY Y2 and Y5 receptor activation and lipid accumulation in murine adipocytes. Neuropeptides 2012, 46:359-366.
121. Liu C.D., et al. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery 1995, 118:229-235.
122. Cadiacio C.L., et al. Hilar neuropeptide Y interneuron loss in the aged rat hippocampal formation. Exp. Neurol. 2003, 183:147-158.
123. Chan-Palay V., et al. Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia. J. Comp. Neurol. 1986, 248:376-394.
124. Coppola J.D., et al. Expression of NPY Y1 and Y5 receptors in the hypothalamic paraventricular nucleus of aged Fischer 344 rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R69-R75.
125. Zoli M., et al. Neurochemical alterations but not nerve cell loss in aged rat neostriatum. J. Chem. Neuroanat. 1993, 6:131-145.
126. Cannizzaro C., et al. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Mol. Brain Res. 2003, 110:169-176.